Abstract 18P
Background
High neutrophil to lymphocyte ratio may reflect the key role of systemic inflammation in enhancing angiogenesis, tumor growth and development of metastasis The role of lymphocytes cells in cancer control is exemplified by the strong association between high densities of tumor-infiltrating lymphocytes and better responses to both, cytotoxic treatments and outcome in patients with breast cancer.
Methods
A total number of files reviewed is 1167 files and a total of 102 breast cancer patients included in this study with histologically proven early stage (T1–2, N0–1, non-metastatic) breast cancer treated in Babylon Oncology Center from January 2009 to September 2014 were considered for this retrospective study. The following data were collected from patient file: age, date of diagnosis, date of recurrence and/or metastasis, follow up period, histological tumor type, tumor size, tumor-node-metastasis stage, expression of estrogen and/or progesterone receptor, HER-2-neu status, metastasis site and with inclusion criteria of Tumor stage up to stage IIA (T1-T2, N0/ T1, N1), follow up for at least 36 months and pre-treatment CBC with differential count.
Results
With mean age of 50.4 ± 11.7 years and minimum follow up 40 months, the overall median DFS was 62 months with 5 – years DFS of 52.5%, stage N0 show significant better DFS compared to stage N1 (P value 0.004), also patients with positive hormonal status show significant better DFS compared to negative hormonal status (P value 0.029), NLR has significant outcome on DFS when increased the ratio leading to declining in DFS (P value 0.006), NLR fair specificity (76.9%) with lower sensitivity (62.2%), with optimal cut point of > 2.194 to predict DFS with better DFS about 16 months (P value 0.0004), and Hazard Ration is 2.5 (P value 0.007), in univariate analysis the significant Hazard Ratio are NLR, N staging and Hormonal status while in multivariate analysis shows only NLR Hazard Ratio with (0.012 P value). In our study PLR neither sensitive nor specific with non-significant P value so it will not be consider as a prognostic index.
Conclusions
Elevated NLR is strongly associated with poor disease free survival of breast cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Iraqi Board for Medical Specialities.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract